Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Amgen_Ventures
|
| gptkbp:advocates_for |
support initiatives
|
| gptkbp:business_model |
partnerships and collaborations
|
| gptkbp:ceo |
Eric Poma
|
| gptkbp:clinical_trial |
gptkb:healthcare_organization
gptkb:Company patient safety Phase 1 research findings therapeutic proteins |
| gptkbp:collaborations |
academic institutions
drug development biomedical research |
| gptkbp:committee |
industry experts
|
| gptkbp:community_engagement |
healthcare initiatives
|
| gptkbp:discovered_by |
innovative approaches
|
| gptkbp:employees |
approximately 50
|
| gptkbp:financial_performance |
financial performance
|
| gptkbp:focus |
therapeutics
|
| gptkbp:founded |
gptkb:2013
|
| gptkbp:future_plans |
clinical development
|
| gptkbp:governed_by |
strategic partnerships
|
| gptkbp:headquarters |
gptkb:Portland,_Oregon
|
| https://www.w3.org/2000/01/rdf-schema#label |
Molecular Templates
|
| gptkbp:innovation |
new therapies
biotechnology field |
| gptkbp:invention |
gptkb:API
biotechnology innovations |
| gptkbp:investment |
market trends
oncology sustainable growth venture capital firms communication strategies public and private funding |
| gptkbp:language_of_instruction |
therapeutic candidates
|
| gptkbp:market |
industry trends
|
| gptkbp:marketing_strategy |
therapeutic areas
growth and innovation |
| gptkbp:mission |
develop innovative therapies
|
| gptkbp:partnership |
collaborative efforts
|
| gptkbp:partnerships |
pharmaceutical companies
|
| gptkbp:platform |
Toxin Body Technology
|
| gptkbp:products |
MT-3724
|
| gptkbp:publishes |
peer-reviewed journals
|
| gptkbp:reach |
international collaborations
|
| gptkbp:receives_funding_from |
gptkb:2018
grants and investments |
| gptkbp:regulatory_compliance |
gptkb:FDA
FDA guidelines |
| gptkbp:research |
drug efficacy
|
| gptkbp:research_areas |
MT-5111
|
| gptkbp:research_focus |
targeted therapies
immuno-oncology |
| gptkbp:side_effect |
patient care improvements
|
| gptkbp:social_responsibility |
ethical practices
|
| gptkbp:specializes_in |
engineered toxin bodies
|
| gptkbp:strategic_importance |
expand pipeline
|
| gptkbp:sustainability_initiatives |
cancer research
|
| gptkbp:symbol |
MTEM
|
| gptkbp:targets |
hematologic malignancies
|
| gptkbp:team |
experienced professionals
|
| gptkbp:technology |
commercialization efforts
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
patient responses
|